Structure−Activity Studies for a Novel Series of Tricyclic Substituted Hexahydrobenz[e]isoindole α1A Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)
摘要:
In search of a uroselective agent that exhibits a high level of selectivity for the alpha(1A) receptor, a novel series of tricyclic hexahydrobenz[e]isoindoles was synthesized. A generic pharmacophoric model was developed requiring the presence of a basic amine core and a fused heterocyclic side chain separated by an alkyl chain. It was shown that the 6-OMe substitution with R, R stereochemistry of the ring junction of the benz[e]isoindole and a two-carbon spacer chain were optimal. In contrast to the highly specific requirements for the benz[e]isoindole portion and linker chain, a wide variety of tricyclic fused heterocyclic attachments were tolerated with retention of potency and selectivity. In vitro functional assays for the alpha(1) adrenoceptor subtypes were used to further characterize these compounds, and in vivo models of vascular vs prostatic tone were used to assess uroselectivity.
[EN] 3-PHENYLPYRROLE ALPHA-1 ADRENERGIC COMPOUNDS<br/>[FR] COMPOSES DE 3-PHENYLPYRROLE [ALPHA-1]-ADRENERGIQUES
申请人:ABBOTT LABORATORIES
公开号:WO1999057122A1
公开(公告)日:1999-11-11
(EN) Compounds having formula (I) are $g(a)1 adrenoreceptor antagonists. Processes for making these compounds, synthetic intermediates employed in these processes and a method for inhibiting $g(a)1 adrenoreceptors and treating benign prostatic hyperplasia (also called benign prostatic hypertrophy or BPH) and other urological diseases such as BOO (bladder outlet obstruction), neurogenic bladder and gynecological syndromes such as dysmenorrhea are disclosed.(FR) L'invention concerne des composés de la formule (I) qui sont des antagonistes de l'adrénorécepteur alpha-1. On décrit des procédés de production desdits composés, des intermédiaires synthétiques utilisés dans lesdits procédés et un procédé d'inhibition des adrénorécepteurs alpha-1 et de traitement de l'hyperplasie prostatique bénigne (également appelée hypertrophie prostatique ou BPH) ou d'autres maladies urologiques, telles que l'obstruction à la sortie de la vessie (BOO), la vessie neurogène ou les syndromes gynécologiques comme la dysménorrhée.